Partial and total monosomal karyotypes in myelodysplastic syndromes: Comparative prognostic relevance among 421 patients

American Journal of Hematology

Volumn 86, Issue 7, 2011, Pages 540-545

  Belli, Carolina B ^a,f   Bengió, Raquel ^a   Aranguren, Pedro Negri ^b   Sakamoto, Francisco ^b   Flores, María G ^c,f   Watman, Nora ^d   Nucifora, Elsa ^e,f   Prates, María V ^e,f   Arbelbide, Jorge ^e   Larripa, Irene ^a  

^a INST DE INVEST HEMATOLOGICAS   (Argentina)

^b Instituto Privado de Hematologia y Hemoterapia   (Argentina)

^c HOSPITAL DURAND   (Argentina)

^d HOSPITAL RAMOS MEJÍA   (Argentina)

^e HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^f Argentinean Society of Hematology   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARGENTINA; ARTICLE; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MONOSOMY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARGENTINA; CHROMOSOME DELETION; CHROMOSOMES, HUMAN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOSOMY; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 79959358531     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22034     Document Type: Article

References (25)

1. Greenberg P, Cox C, LeBeau M, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
2. Morel P, Hebbar M, Lai J, et al. Cytogenetic analysis has strong independent prognostic value in the novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases. Leukemia 1993; 7: 1315-1323.
3. Solé F, Luño E, Sanzo C, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 2005; 90: 1168-1178.
4. Bennett J, Catovsky D, Daniel M, et al. Proposals for the classification of the myelodysplastic Syndromes. Br J Haematol 1982; 51: 189-199.
5. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissue: Report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849.
6. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009; 114: 937-951.
7. Solé F, Espinet B, Sanz G, et al. Grupo Cooperativo Español de Citogenética Hematológica: Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Br J Haematol 2000; 108: 346-356.
8. Irons R, Wang X, Gross S, et al. Prevalence of MDS subtypes in Shanghai, China: A comparison of the World Health Organization and French American British Classifications. Leuk Res 2006; 30: 769-775.
9. Mufti GJ, Stevens JR, Oscier DG, et al. Myelodysplastic syndromes: A scoring system with prognostic significance. Br J Haematol 1985; 59: 425-433.
10. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503-3510.
11. Pfeilstöcker M, Reisner R, Nösslinger T, et al. Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics. Br J Haematol 1999; 106: 455-463.
12. de Souza Fernández T, Ornellas M, Otero de Carvalho L, et al. Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukemia. Leuk Res 2000; 24: 839-848.
13. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood 2007; 110: 4385-4395.
14. Pozdnyakova O, Miron PM, Tang G, et al. Cytogenetic abnormalities in a series of 1, 029 patients with primary myelodysplastic syndromes: A report from the US with a focus on some undefined single chromosomal abnormalities. Cancer 2008; 113: 3331-3340.
15. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: A better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26: 4791-4797.
16. Valent P, Horny HP, Bennett J, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 2007; 31: 727-736.
17. Shaffer LG, Slovak ML, Campbell LJ, editors. ISCN 2009: An International System for Human Cytogenetic Nomenclature. Basel: S. Karger; 2009.
18. Chun K, Hagemeijer A, Iqbal A, Slovak ML. Implementation of standardized international karyotype scoring practices is needed to provide uniform and systematic evaluation for patients with myelodysplastic syndrome using IPSS criteria: An International Working Group on MDS Cytogenetics Study. Leuk Res 2010; 34: 160-165.
19. Parlier V, van Melle G, Beris P, et al. Prediction of 18-month survival in patients with primary myelodysplastic syndrome. A regression model and scoring system based on the combination of chromosome findings and Bournemouth score. Cancer Genet Cytogenet 1995; 81: 158-165.
20. Müller-Berndorff H, Haas P, Kunzmann R, et al. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis. Ann Hematol 2006; 85: 502-513.
21. Belli C, Acevedo S, Bengio R, et al. Detection of risk groups in myelodysplastic syndrome. A multicenter study. Haematologica 2002; 87: 9-16.
22. Matsuda A, Germing U, Jinnai I, et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood 2005; 106: 2633-2640.
23. Lorand-Metze I, Pinheiro M, Ribeiro E, et al. Factors influencing survival in myelodysplastic syndromes in Brazilian population: Comparison of FAB and WHO classifications. Leuk Res 2004; 28: 587-594.
24. Intragumtornchai T, Prayoonwiwat W, Swasdikul D, et al. Myelodysplastic Syndromes in Thailand: A retrospective pathologic and clinical analysis of 117 cases. Leuk Res 1998; 22: 453-460.
25. Lau LG, Chng WJ, Liu TC, et al. Clinico-pathological analysis of myelodysplastic syndromes according to French-American-British classification and International Prognostic Scoring System. Ann Acad Med Singapore 2004; 33: 589-595.